Early intermittent hyperlipidemia significantly accelerates atherosclerosis by disrupting macrophage function, highlighting the need for early cholesterol management.
Bayer’s Kerendia cuts heart death, failure and hospitalization by 16% in Phase 3 trial
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS